NCT03595917 2025-11-04ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CMLDana-Farber Cancer InstitutePhase 1 Recruiting40 enrolled
NCT01643603 2020-12-17Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic MalignanciesBarbara Ann Karmanos Cancer InstitutePhase 1 Terminated5 enrolled